Beta-blockers post-MI: an example of age discrimination?

Stephen Gottlieb1

  • 1Department of Cardiology, University of Maryland Medical Center, Baltimore, MD 21201, USA. sgottlie@medicine.umaryland.edu

Postgraduate Medicine
|August 12, 2009
PubMed

Insights

Beta-blocker therapy effectively improves survival in post-myocardial infarction patients across all age groups, including the elderly. Despite underutilization in older populations, age does not diminish the benefits of these crucial medications.

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • Pharmacology

Background:

  • Beta-blockers are proven effective post-myocardial infarction.
  • Clinical trials often exclude elderly populations, limiting data on their specific outcomes.
  • Underutilization of beta-blockers in the elderly is a significant concern.

Purpose of the Study:

  • To evaluate the efficacy of beta-blocker therapy in elderly patients post-myocardial infarction.
  • To determine if age affects the survival benefits of beta-blockers.
  • To address the underutilization of beta-blockers in geriatric populations.

Main Methods:

  • Analysis of data from older patients in large clinical trials.
  • Review of smaller trials and retrospective studies focusing on elderly cohorts.
  • Comparative analysis of beta-blocker efficacy across different age demographics.

Main Results:

  • Beta-blocker therapy demonstrates consistent survival benefits irrespective of patient age.
  • Data suggest that the therapeutic advantage of beta-blockers is maintained in patients over 80 years old.
  • Despite data limitations, a clear association between beta-blocker use and improved survival in all age groups was observed.

Conclusions:

  • Beta-blocker therapy is beneficial for elderly patients following myocardial infarction.
  • Age is not a limiting factor for the positive impact of beta-blockers on survival.
  • Increased utilization of beta-blockers in the elderly population is warranted to improve outcomes.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Stereotypes, Prejudice, and Discrimination02:55

Stereotypes, Prejudice, and Discrimination

Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who are...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...